Bristol-Myers Squibb Company (NYSE: BMY) announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trader Talk Trading Halts

Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 FailureAugust 8, 2016 6:37 AM Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to EqualweightAugust 5, 2016 1:24 PM Deutsche Bank Comments on Bristol-Myers Squibb (BMY) Opdivo News; Analyst Says Merck (MRK) Not Guaranteed to be Alone in Front-Line Setting August 5, 2016 11:25 AM Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)August 5, 2016 10:00 AM SunTrust Robinson Humphrey Downgrades Bristol-Myers Squibb Co. (BMY) to NeutralAugust 5, 2016 9:30 AM Bristol-Myers Squibb (BMY) Falls 22% After Shares Resume TradingAugust 5, 2016 8:32 AM Merck (MRK) Surges After Bristol-Myers Squibb's (BMY) CheckMate -026 Trial FailsAugust 5, 2016 8:24 AM Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung CancerAugust 5, 2016 8:20 AM Bristol-Myers Squibb (BMY) opening delayed with news pendingAugust 5, 2016 7:54 AM Allergan's cash-use plan, pipeline could add to share runAugust 4, 2016 1:16 PM